Clinical trial
Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in…
NCT00163540 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00163540 |
|---|---|
| Title | Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225) |
| Official title | Open-Label, Follow-up, Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated Using a Rapid Immunization Schedule (Follow-up to Study 225) |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Encephalitis, Tick-borne |
| Intervention type | Biological |
| Interventions | Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl |
| Start date | May 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | Sep 14, 2005 |
| Last update posted | May 21, 2015 |
| Countries | Belgium |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: